Streetbeat News

Price Targets

DOW

Deutsche Bank analyst David Begleiter maintains a Hold rating on Dow Inc. (NYSE:DOW) and lowers the price target from $57 to $53.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 6:00 pm

EXAS

Exact Sciences (NASDAQ:EXAS) has received mixed analyst ratings over the past three months, with a trend towards lowering price targets. The average 12-month price target is now $74, down from $84.86. Analysts have adjusted their ratings in response to market dynamics and company performance. Exact Sciences, known for its cancer screening products, has shown revenue growth but lags behind industry peers. The company's financials reveal challenges in ROE and ROA, despite a strong net margin and prudent debt management.

Portfolio Pulse from Benzinga Insights

September 12, 2024 | 6:00 pm

BILL

21 analysts have evaluated BILL Holdings (NYSE:BILL) over the past three months, showing a mix of bullish and bearish perspectives. The average 12-month price target has decreased by 11.35% to $71.05. Analysts have adjusted their ratings and price targets, reflecting dynamic market conditions and company performance. BILL Holdings has shown a 16.11% revenue growth rate, a net margin of 2.21%, and a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

September 12, 2024 | 6:00 pm

NRXP

Ascendiant Capital has maintained a Buy rating on NRX Pharmaceuticals and raised the price target from $43 to $44, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 5:58 pm

GIS

B of A Securities analyst Bryan Spillane maintains a Neutral rating on General Mills (NYSE:GIS) but raises the price target from $68 to $75.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 5:56 pm

AXON

Axon Enterprise shares are experiencing an upward trend following JMP Securities' decision to increase its price target from $375 to $430.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 5:56 pm

FULC

B of A Securities has downgraded Fulcrum Therapeutics from Neutral to Underperform and significantly lowered its price target from $10 to $2.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 5:55 pm

PCH

PotlatchDeltic shares rose following an upgrade by B of A Securities from Neutral to Buy, with a new price target of $51.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 5:54 pm

VNO

Vornado Realty shares increased following a price target upgrade by Goldman Sachs from $21.5 to $23.5.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 5:52 pm